Immunotherapy

A Phase 2 trial tested the combination of Azacitidine and Pembrolizumab as a second-line treatment for advanced pancreatic ductal adenocarcinoma. The goal was to “prime” the tumor with Azacitidine to make it more visible to the immune system and improve response to immunotherapy. The study enrolled 36 patients, with 31 evaluable for efficacy. Results showed […]

Pumitamig (BNT327) is a new bispecific antibody showing promise for patients with metastatic triple-negative breast cancer, including those who are PD-L1 negative and previously had limited immunotherapy options. The drug works by targeting two pathways at once: it blocks PD-L1 to unleash T cells against tumors and inhibits VEGF to stop tumor blood vessel growth.

Researchers at University of California San Francisco have developed a new approach that could transform CAR-T cell therapy by turning it into a simple injection instead of a complex lab procedure. Traditional CAR-T therapy requires removing a patient’s immune cells, modifying them in a lab, and reinfusing them weeks later. This process is slow, expensive,

Long-term results from the COMPASSION-03 trial show that cadonilimab, a first-in-class PD-1/CTLA-4 bispecific antibody, offers lasting survival benefits for patients with recurrent or metastatic cervical cancer who have failed prior chemotherapy. Patients who achieved complete responses had a 100% survival rate at 24 months, while partial responders showed a 63% survival rate, with a median

Three-year follow-up results from the Phase 3 RATIONALE-309 trial show that adding tislelizumab to chemotherapy significantly improves survival in patients with recurrent or metastatic nasopharyngeal carcinoma. Patients receiving the combination of tislelizumab with chemotherapy lived longer and had better disease control compared to chemotherapy alone. Median progression-free survival was 9.6 months versus 7.4 months, while

Extended follow-up from a Phase 2a trial shows that CAN-2409, an experimental “in situ” tumor vaccine, may significantly improve survival in patients with advanced non–small cell lung cancer (NSCLC) who no longer respond to immune checkpoint inhibitors. At 24 months, 50% of patients were still alive, an increase from earlier results. Median overall survival reached

A new study suggests that the gut microbiome may play a key role in the success of CAR T-cell therapy for patients with relapsed/refractory diffuse large B-cell lymphoma (R/R-DLBCL). Researchers studied 47 Asian patients and found that certain gut bacteria and metabolites were linked to both treatment effectiveness and side effects. Patients who responded well

Immunotherapy is rapidly changing the treatment of Cutaneous Squamous Cell Carcinoma, a skin cancer that has traditionally been treated mainly with surgery. Experts say immune checkpoint inhibitors are now shifting systemic therapy from a last-resort option to a treatment used earlier in the disease course. Doctors are increasingly using immunotherapy before surgery, a strategy known

A phase 2 clinical trial (NCT04718883) has shown promising results for relmacabtagene autoleucel (relma-cel), an anti-CD19 CAR T-cell therapy, in patients with relapsed or refractory mantle cell lymphoma who had already failed at least two previous treatments, including BTK inhibitors. The study included 59 heavily pretreated patients with a median age of 59. The therapy

A new study identifies the protein SLFN5 as a key barrier to effective treatment in Pancreatic Ductal Adenocarcinoma (PDAC). SLFN5 acts as an “intracellular immune checkpoint,” helping tumors remain “cold” by evading immune attack and resisting standard therapies. High levels of SLFN5 are linked to poor patient survival. While Interferons normally activate anti-tumor defenses, SLFN5